Biolidics (SGX:8YY) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Biolidics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Biolidics's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.00.

Biolidics's long-term debt to total assets ratio declined from Dec. 2023 (1.09) to Dec. 2024 (0.00). It may suggest that Biolidics is progressively becoming less dependent on debt to grow their business.

Biolidics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Biolidics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biolidics LT-Debt-to-Total-Asset Chart

Biolidics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.22

0.26

0.29

1.09

Biolidics Quarterly Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															1.09	0.61	0.37	0.15	-

Biolidics LT-Debt-to-Total-Asset Calculation

Biolidics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	0.005	/	3.965
	=	0.00

Biolidics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	0.005	/	3.965
	=	0.00

Biolidics (SGX:8YY) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Biolidics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Biolidics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Biolidics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biolidics Ltd (SGX:8YY) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

18 Howard Road, No. 11-09 Novelty BizCentre, Singapore, SGP, 369585

Website

https://www.biolidics.com

Biolidics Ltd is engaged in technology development, technology transfer, marketing, sale and distribution of biomedical technology, life, and medicine science-related products and services, and investment holding. The company's business segments are; Cancer, Infectious diseases, Laboratory services, and Corporate. The majority of the company's revenue is generated from the laboratory services segment which involves the business, operation, and provision of laboratory services to customers. Its operations are spread across Singapore, Japan, China, Europe, the United States, Hong Kong, the Philippines, Indonesia, and Others.

Biolidics Headlines

No Headlines